SWI is a therapeutic medical device startup having strong relationship with Tohoku University(Japan). Making progress on Clinical Studies of both LIPUS and SWCS (less invasive therapies) that have been developed by Professor Emeritus Hiroaki Shimokawa group, we aim to realize our innovative devices both with Tohoku University and Medical Device Company.
LIPUS(low power pulsed ultrasound)
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhaces angiogenesis in ischemic tissue and induce spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.
SWCS(shock wave ablation catheter system)
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.